Clinical Efficacy and Complication Rate of Sunitinib 2/1 Versus 4/2 Schedule for the Treatment of Metastatic Renal Cell Cancer: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Clinical Efficacy and Complication Rate of Sunitinib 2/1 Versus 4/2 Schedule for the Treatment of Metastatic Renal Cell Cancer: A Systematic Review and Meta-Analysis

Published:2019-10 Issue:5 Volume:17 Page:319-331
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Chen Chenglong,Fang Huan,Jiao Yurui,Zhou Yi,Guo Qiang,Lv Zhi^ORCID

Funder

Shanxi Medical University

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Renal cell carcinoma: review of etiology, pathophysiology and risk factors;Petejova;Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2016

2. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

3. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney;Aydin;Am J Surg Pathol,2010

4. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction;Yoo;Jpn J Clin Oncol,2010

5. Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study;Guo;Onco Targets Ther,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy;ESMO Open;2022-04

2. Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy;Expert Opinion on Drug Safety;2021-08-30

3. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs;Cancer Letters;2021-03

4. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study;BMC Cancer;2021-01-05

5. lncRNA 00312 Attenuates Cell Proliferation and Invasion and Promotes Apoptosis in Renal Cell Carcinoma via miR-34a-5p/ASS1 Axis;Oxidative Medicine and Cellular Longevity;2020-03-27